Read More Pharma Industry News InhaleRx (ASX: IRX) unveils oral esketamine therapy for depression but stock sinks 22% amid investor caution InhaleRx launches SRX-25 oral esketamine therapy for depression, plans rebrand and raises capital despite 22% stock plunge. Learn what this could mean for investors. byVenkateshNovember 26, 2025